Хлебные крошки
- Главная
-
Аналитика
-
Акции
Акции внутренные
Aziyo Biologics, Inc. AZYO
$2.28
На 18:03, 12 мая 2023
+349.56%
Потенциал через год
Ранг: 3
Ключевые показатели
-
Marketcap
37237460.00000000
-
week52high
9.01
-
week52low
1.10
-
Revenue
49187000
-
P/E TTM
-1
-
Beta
-0.29788700
-
EPS
-2.50000000
-
Last Dividend
0.00000000
-
Next Earnings Date
10 мая 2023 г. в 20:00
Описание компании
Aziyo Biologics, Inc., a regenerative medicine company, focuses on the development of regenerative medical products to address the implantable electronic device/cardiovascular, orthopedic/spinal repair, and soft tissue reconstruction markets. It offers CanGaroo that combines the envelope with antibiotics and is designed to reduce the risk of infection following surgical implantation of an electronic device. The company also provides cardiovascular products, such as ProxiCor for use as an intracardiac patch or pledget for tissue repairs; Tyke for use in neonates and infants to repair pericardial structures; and VasCure, a patch material to repair or reconstruct the peripheral vasculature, including the carotid, renal, iliac, femoral, and tibial blood vessels for cardiovascular, vascular, and general surgeons. In addition, it offers Fiber VBM, ViBone, and OsteGro V that are human tissue-derived bone allografts designed to protect and preserve native bone cells; and SimpliDerm, a pre-hydrated HADM designed to repair or replacement of damaged or inadequate integumental tissues. Further, the company provides contract manufacturing services for various products to corporate customers. It sells its products to hospitals and other healthcare facilities through its direct sales force, commercial partners, and independent sales agents. The company was incorporated in 2015 and is headquartered in Silver Spring, Maryland.
Рекомендации
аналитиков
Рекомендации аналитиков
| Grading company | New grade | Previous grade | Recommendation date |
|---|---|---|---|
| Cowen & Co. | Outperform | Outperform | 04 мар 2022 г. |
| Truist Securities | Buy | 02 ноя 2020 г. | |
| Piper Sandler | Overweight | 02 ноя 2020 г. | |
| Cowen & Co. | Outperform | 02 ноя 2020 г. | |
| Cantor Fitzgerald | Overweight | 02 ноя 2020 г. | |
| Truist Securities | Buy | Buy | 16 ноя 2022 г. |
| Piper Sandler | Overweight | Overweight | 15 ноя 2022 г. |
Свежие комментарии
Свежие комментарии
Оставьте свой голос
Оставьте свой голос
Анонимное голосование
Будет ли рост российского рынка к концу года?
-
Да
87% -
Нет
12%
Проголосовал 8 человек
Новостная лента
компании
Insider Summary
Insider Summary
| Reporting Name | Acquistion/Disposition | Owned | Transacted | Transaction Date |
|---|---|---|---|---|
| HighCape Partners GP II, LLC | A | 17533 | 17533 | 22 дек 2022 г. |
| HighCape Capital, L.P. | A | 17533 | 17533 | 22 дек 2022 г. |
| Colpman David | A | 3098 | 3098 | 15 дек 2022 г. |
| Makes Brigid | A | 2000 | 2000 | 09 дек 2022 г. |
| HighCape Capital, L.P. | A | 5597604 | 735000 | 05 дек 2022 г. |
| Ferguson Matthew | A | 45217 | 2000 | 05 дек 2022 г. |
| Ferguson Matthew | A | 43217 | 20000 | 05 дек 2022 г. |
| Ferguson Matthew | A | 23217 | 6000 | 02 дек 2022 г. |
| Williams Michelle LeRoux | A | 90000 | 90000 | 20 окт 2022 г. |
| Colpman David | A | 28513 | 28513 | 20 окт 2022 г. |
Новостная лента
Aziyo Biologics, Inc. (AZYO) Upgraded to Buy: Here's What You Should Know
Zacks Investment Research
26 янв 2023 г. в 13:33
Aziyo Biologics, Inc. (AZYO) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Aziyo Biologics to Participate in Upcoming Investor Conferences
GlobeNewsWire
21 ноя 2022 г. в 16:05
SILVER SPRING, Md., Nov. 21, 2022 (GLOBE NEWSWIRE) -- Aziyo Biologics, Inc. (Nasdaq: AZYO), a biologics company with a portfolio of regenerative products aimed at improving compatibility between medical devices and the patients they treat, today announced that management will be participating in the following investor conferences:
Aziyo Biologics, Inc. (AZYO) Q3 2022 Earnings Call Transcript
Seeking Alpha
15 ноя 2022 г. в 16:38
Aziyo Biologics, Inc. (NASDAQ:AZYO ) Q3 2022 Results Conference Call November 14, 2022 4:30 PM ET Company Participants Matt Steinberg - Fin Partners Randy Mills - CEO Matt Ferguson - CFO Conference Call Participants Josh Jennings - Cowen Simran Kaur - Piper Sandler David Rescott - Truist Securities Operator Good day, ladies and gentlemen, and thank you for standing by. Welcome to the Aziyo Biologics Third Quarter 2022 Earnings Conference Call.
Aziyo Biologics, Inc. (AZYO) Reports Q3 Loss, Tops Revenue Estimates
Zacks Investment Research
14 ноя 2022 г. в 18:48
Aziyo Biologics, Inc. (AZYO) delivered earnings and revenue surprises of -10.61% and 1.55%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
Aziyo Biologics to Present at the Inaugural Gilmartin Group Emerging Growth Company Showcase
GlobeNewsWire
17 авг 2022 г. в 16:05
SILVER SPRING, Md., Aug. 17, 2022 (GLOBE NEWSWIRE) -- Aziyo Biologics, Inc. (Nasdaq: AZYO), a commercial-stage regenerative medicine company, today announced the company will present at the upcoming Inaugural Gilmartin Group Emerging Growth Company Showcase, taking place virtually. Members of management are scheduled to present on Wednesday, August 31, 2022 at 10:30 am ET / 7:30 am PT.